Impact of treatment prior to allogeneic transplantation of hematopoietic stem cells in patients with myelodysplastic syndrome: results of the latin american bone marrow transplant registry
The role of bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) has been suggested, but there is some controversy regarding the influence of treatment response on transplant outcomes1. Considering this context, here we have investigated the influence of treatment prior to HSCT in patients with MDS.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Fernando Barroso Duarte, Anna Thawanny Gadelha Moura, Vaneuza Ara újo Moreira Funke, Virgílio Antônio Rensi Colturato, Nelson Hamerschlak, Neysimélia Costa Vilela, Luiz Fernando Lopes, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, R Tags: Brief Article Source Type: research
More News: Biology | Bone Marrow Transplant | Chemotherapy | Hematology | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants